Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143509 |
| CAS No | NA |
| Mol.F. | C18H13ClN4O6 |
| Mol.Wt. | 416.77 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143510 |
| CAS No | NA |
| Mol.F. | C21H17ClN4O6 |
| Mol.Wt. | 456.84 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143511 |
| CAS No | NA |
| Mol.F. | C18H14ClN5O5 |
| Mol.Wt. | 415.79 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143512 |
| CAS No | NA |
| Mol.F. | C21H16ClN5O4 |
| Mol.Wt. | 437.84 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143513 |
| CAS No | NA |
| Mol.F. | C18H14ClN5O5 |
| Mol.Wt. | 415.79 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143514 |
| CAS No | NA |
| Mol.F. | C20H18ClN5O5 |
| Mol.Wt. | 443.84 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143515 |
| CAS No | NA |
| Mol.F. | C11H9N3O4 |
| Mol.Wt. | 247.21g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143516 |
| CAS No | NA |
| Mol.F. | C20H18ClN5O5 |
| Mol.Wt. | 443.84 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143517 |
| CAS No | NA |
| Mol.F. | C24H15ClN4O5 |
| Mol.Wt. | 474.86 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143518 |
| CAS No | NA |
| Mol.F. | C21H18ClN5O6 |
| Mol.Wt. | 471.85 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143519 |
| CAS No | NA |
| Mol.F. | C24H17ClN4O6 |
| Mol.Wt. | 492.87 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143520 |
| CAS No | NA |
| Mol.F. | C19H16ClN5O5 |
| Mol.Wt. | 429.82 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143521 |
| CAS No | NA |
| Mol.F. | C20H16ClN4O4 |
| Mol.Wt. | 441.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143522 |
| CAS No | NA |
| Mol.F. | C20H16ClN5O4 |
| Mol.Wt. | 425.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143523 |
| CAS No | NA |
| Mol.F. | C13H17N3O4 |
| Mol.Wt. | 279.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143524 |
| CAS No | NA |
| Mol.F. | C14H17N3O5 |
| Mol.Wt. | 307.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |